BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 11197208)

  • 1. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.
    Capizzi RL; Oster W
    Int J Hematol; 2000 Dec; 72(4):425-35. PubMed ID: 11197208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Radioprotective effects on head and neck tumors of amifostine--a broad-spectrum cytoprotection].
    Huang R; Yu H; Kuang A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2002 Dec; 19(4):708-11. PubMed ID: 12561384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of amifostine: from cytoprotectant to therapeutic agent.
    Santini V; Giles FJ
    Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amifostine: the first selective-target and broad-spectrum radioprotector.
    Kouvaris JR; Kouloulias VE; Vlahos LJ
    Oncologist; 2007 Jun; 12(6):738-47. PubMed ID: 17602063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
    Bourhis J; Rosine D
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amifostine and combined-modality therapeutic approaches.
    Mehta MP
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):95-101. PubMed ID: 10348267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurologic protection by amifostine.
    DiPaola RS; Schuchter L
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):82-8. PubMed ID: 10348265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioprotective effects of amifostine.
    Wasserman T
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):89-94. PubMed ID: 10348266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
    Capizzi RL
    Semin Oncol; 1994 Oct; 21(5 Suppl 11):8-15. PubMed ID: 7973776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future development of amifostine as a radioprotectant.
    Werner-Wasik M
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
    Culy CR; Spencer CM
    Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future development of amifostine in cancer treatment.
    Alberts DS; Bleyer WA
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):90-9. PubMed ID: 8783674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
    Kurbacher CM; Mallmann PK
    Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
    Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
    Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amifostine and hematologic effects.
    Sriswasdi C; Jootar S; Giles FJ
    J Med Assoc Thai; 2000 Apr; 83(4):374-82. PubMed ID: 10808697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amifostine: drug profile and nursing implications of the first pancytoprotectant.
    Viele CS; Holmes BC
    Oncol Nurs Forum; 1998 Apr; 25(3):515-23. PubMed ID: 9568606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trials of amifostine and radiotherapy: effect on survival?
    Bourhis J; Thephamongkhol K; Pignon JP
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):62-6. PubMed ID: 15726526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
    Hensley ML; Hagerty KL; Kewalramani T; Green DM; Meropol NJ; Wasserman TH; Cohen GI; Emami B; Gradishar WJ; Mitchell RB; Thigpen JT; Trotti A; von Hoff D; Schuchter LM
    J Clin Oncol; 2009 Jan; 27(1):127-45. PubMed ID: 19018081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.